AstraZeneca Announced Earlier, Truqap Plus Faslodex Approved In Japan For Patients With Advanced HR-positive Breast Cancer
Author: Charles Gross | March 27, 2024 04:56am
AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy
Approval based on CAPItello-291 results which showed Truqap plus Faslodex reduced the risk of disease progression or death by 50% vs. Faslodex alone in the biomarker-altered population.
Posted In: AZN EWJ